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A B S T R A C T
INTRODUCTION: Gestational diabetes mellitus (GDM) is associated with fetoplacental endothelial dysfunction,
which may be induced by hyperglycemia. We hypothesized that endothelial exosomes, which are extracellular
nanovesicles aﬀecting endothelial function, play a role in the high glucose (HG)-induced endothelial dysfunc-
tion.
METHODS: Exosomes were isolated from HUVECs incubated with basal glucose (5.5 mmol/L; HUVEC- BG; exo-
BG) and from HUVECs incubated with HG for 24 h (25mmol/L; HUVEC-HG; exo-HG) in exosome-free medium.
Exosomes were isolated and characterized by ultracentrifugation, sucrose gradient, electron microscopy, na-
notracking analysis and Western blotting. HUVEC-BG and HUVEC-HG were exposed to exo-BG and exo-HG in
two diﬀerent concentrations: 5 μg and 1 μg exosome protein/mL. The exosomal eﬀect on endothelial cell
function was determined by wound healing assay, expression of endothelial nitric oxide synthase (eNOS), human
cationic amino acid transporter type 1 (hCAT-1), vascular endothelial growth factor (VEGF) and intracellular
adhesion molecule type 1 (ICAM-1) by Western blotting, qPCR or ﬂow cytometry.
RESULTS: HG increased the exosomal release from HUVECs, endothelial wound healing and expression of
phosphorylated (P∼Ser1177)-eNOS, hCAT-1, VEGF and ICAM-1. Exo-HG also increased endothelial cell wound
healing, P∼Ser1177-eNOS, hCAT-1 and ICAM-1 expression in HUVEC-BG. Exo-BG reverted the eﬀect of HG on
endothelial cell wound healing and hCAT-1 mRNA expression to normal values.
DISCUSSION: Our results show that HG may induce endothelial dysfunction in HUVECs and that exosomes from
HUVEC-HG mimicked some of the eﬀects of HG. This study contributes to the unraveling of the mechanism by
which hyperglycemia aﬀects the fetoplacental vasculature in GDM.
1. Introduction
Gestational diabetes mellitus (GDM) is one of the most common
pregnancy complications in the world [1], aﬀecting 2–6% of all preg-
nancies in Europe [2]. It is associated with several fetal and maternal
complications such as an increased risk for preeclampsia, preterm de-
livery and fetal macrosomia [3,4]. Moreover, GDM is associated with
long-lasting health consequences for both mother and child, such as a
chance to develop type 2 diabetes in later life [5–7].
Key in the complications associated with GDM is probably vascular
dysfunction in both the maternal and fetoplacental endothelium [1,8].
In human umbilical vein endothelial cells (HUVECs) from women di-
agnosed with GDM, an impaired endothelial function has been de-
monstrated. Endothelial dysfunction is characterized by impaired en-
dothelial-dependent vasodilation caused by a loss in NO bioactivity
[9,10]. Various changes associated with low NO bioactivity have been
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found in the L-Arginine/nitric oxide (NO) signaling pathway in HUVECs
derived from GDM pregnancies, such as increased expression of human
cationic amino acid transporter type 1 (hCAT-1), increased NO pro-
duction and increased phosphorylated Ser1177 endothelial nitric oxide
synthase (P∼Ser1177-eNOS) [9,11], as compared to HUVECs from
healthy pregnancies.
However, the mechanisms behind the GDM induced fetal-placental
endothelial dysfunction are largely unknown. Since GDM is character-
ized by maternal and fetal hyperglycemia [1,12–14], high glucose (HG)
could be one of the factors inducing endothelial dysfunction in GDM
[12,15]. Indeed, previous studies in HUVECs have shown that HG in-
creased the expression of P∼Ser1177-eNOS and hCAT-1, as well as en-
hanced the transport of L-arginine and the production of NO [16],
suggesting an important role for high glucose on fetoplacental en-
dothelial dysfunction in GDM.
Another mechanism that could be responsible for fetoplacental en-
dothelial dysfunction may be exosomes. An enhanced release of exo-
somes and a change in exosomal cargo have recently been implicated in
several vascular disorders [17–19]. Exosomes are extracellular nano-
vesicles, which are released by diﬀerent cell types, including placental
and endothelial cells, cells such as HUVECs [20,21]. Exosomal cargo
include proteins, mRNAs and microRNAs [22]. Exosomes can transfer
this cargo from one cell to another, thus acting as cell-to-cell commu-
nicators [23,24]. In this way, exosomes are for instance able to mod-
ulate endothelial cell function [25].
In the present study, we tested the hypothesis that high D-glucose
induces similar endothelial dysfunction as seen in HUVECs of GDM
pregnancies and, since our previous study showed a role for exosomes
in inducing endothelial dysfunction in HUVECs of GDM [21], we hy-
pothesized that this eﬀect of high glucose may be mimicked by en-
dothelial exosomes derived from HUVECs incubated with high glucose.
To this end, we incubated HUVECs with basal and high levels of D-
glucose and isolated the exosomes. These exosomes were incubated
with HUVECs (both under basal or high glucose levels) after which
protein and mRNA levels were studied of hCAT-1, eNOS and
P∼Ser1177-eNOS and VEGF. To determine endothelial cell functionality
and activation, we performed a wound healing assay and evaluated
ICAM-1 expression in HUVECs incubated with exosomes.
2. Material and methods
2.1. Cell culture and treatment
Human umbilical vein endothelial cells (HUVECs) from normal
pregnancies were provided by the Endothelial Cell Facility of the UMCG
(Groningen, Netherlands). HUVECs were isolated by collagenase di-
gestion (0.25mg/mL Collagenase Type II from Clostridium histoly-
ticum; Boehringer, Mannheim, Germany), as previously described [26].
HUVECs were cultured in RPMI medium (Lonza, Basel, Switzerland)
supplemented with 2mmol/L L-glutamine, 5 U/mL heparin, 100 IE/mL
penicillin, 100 μg/mL streptomycin, 50 μg/mL crude ECGF solution,
and 20% FCS (37 °C, 5% CO2) on 1% gelatin-precoated tissue culture
ﬂasks (Corning® Costar®; Sigma-Aldrich, Zwijndrecht, The Netherlands).
HUVECs in passage 2 with 70% conﬂuence in T75 (12mL) culture
ﬂask were incubated with exosome-free media for 24 h, with addition of
D-glucose (HUVEC-HG; 25mmol/L D-glucose (high glucose, HG) or
without addition of D-glucose (HUVEC-BG; 5.5mmol/L D-glucose (basal
glucose, BG). Exosome free medium was obtained after ultra-
centrifugation of HUVECs culture medium (100000 g at 4 °C for
70min), supernatant was ﬁltered (0.22 μm ﬁlter) and pellet was dis-
carded. After 24 h, HUVECs cell number was not diﬀerent when in-
cubated in BG compared with HG medium (not shown), therefore
exosomes were isolated from the same number of HUVECs in both
conditions.
2.2. Exosome isolation and puriﬁcation
Exosomes were isolated according to Théry and colleagues [27]. We
isolated exosomes from supernatant (40mL) of 7 HUVECs cell cultures
with equal numbers of umbilical cords incubated in exosome-free
medium. Exosomes were isolated and puriﬁed by diﬀerential ultra-
centrifugation as recently described in primary cultured HUVECs [21].
In brief, supernatant was ﬁltered through a 0.22 μm ﬁlter and then,
centrifugation was performed at 2000 g at 4 °C for 30min, followed by
12000 g at 4 °C for 45min. Then, the supernatant was centrifuged at
110000 g at 4 °C for 70min (Centrikon T-1080 ultracentrifuge, Kontron
Instruments, SW 41 rotor). The pellet was resuspended in phosphate
buﬀer solution (PBS, 1mmol/L, pH 7.4) and centrifuged at 110000 g at
4 °C for 70min. The exosome pellet was resuspended in sucrose/HEPES
(hydroxyethyl piperazineethanesulfonic acid) 2mol/L and subse-
quently puriﬁed using a discontinuous sucrose gradient (2–0.25mol/L).
Thus, exosomes were mixed with 2mL of 2mol/L sucrose in HEPES and
placed on the bottom of a SW41 centrifuge tube, overlaid in a solution
with 1.5 mL of 1.35mol/L sucrose, 0.5 mL of 1.28mol/L sucrose, 1 mL
of 1.15mol/L sucrose, and 5mL of 0.25mol/L sucrose, and ultra-
centrifuged for 16 h at 210 000 g at 4 °C. Thus, 12 fractions were col-
lected with 1mL sucrose and refractive index was measured. After this,
all fractions were washed and ultracentrifuged again with PBS at
110 000 g at 4 °C for 70min. Fraction 11 showed ﬂoating density for
exosomes (1.16 g/mL) and exosomal markers by western blotting and
was used for the experiments described below. At the end of each iso-
lation (n= 7), the ﬁnal pellet was resuspended in 300 μL of PBS and
stored at −80 °C for later incubation experiments with HUVECs. The
exosomal protein concentration was determined using the BSA™ Protein
Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA)
(around∼ 0.35 μg/μL per isolation).
2.3. Preparation of exosomes for transmission electron microscopy (TEM)
Aliquots (10 μL) of the exosomal suspension was allowed to adhere
on freshly prepared Formvar coated 200 mesh electron microscopy
grids for 2min. After draining the liquid with a ﬁlter paper, samples
were stained for 1min on a drop of 2% ammonium molybdate in water.
After draining the liquid and airdrying for 5min, samples were ex-
amined in a FEI Cm100 transmission electron microscope operated at
80 KV. Pictures were taken with a Morada camera using Olympus-sis
software.
2.4. Nanoparticle tracking analysis
Quantiﬁcation and size distribution of exosomes was done using
Nano Tracking Analysis (NTA) equipped with a 405 nm laser with
LM14 module (NanoSight NTA 3.0 Nanoparticle Tracking, Version 3.0).
Samples (100 μL) were diluted with PBS (1/10) prior to analysis in
order to obtain particle distribution of particles per image (50 particles
per image). Samples were measured using capture 60 and repeat 5.
Settings were kept constant in all samples. Each video was analyzed to
get the mean particle size and the concentration of particles.
2.5. Western blotting of exosomes
Exosomal pellets isolated from HUVEC-BG and HUVEC-HG were
prepared for western blotting. Exosome pellets isolated from BG and HG
HUVECs were lysed with RIPA buﬀer (1×) (Radio-
Immunoprecipitation Assay buﬀer, 25mmol/L Tris•HCl pH 7.6,
150mmol/L NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS
(Sodium dodecyl sulfate) (Pierce®RIPA Buﬀer, Thermo Fisher Scientiﬁc
Inc, Landsmeer, Netherlands) at room temperature for 5min and then
loading buﬀer (5×) was added to the samples and incubated at 95 °C
for 5min. Aliquots of 20 μg of exosomal protein per well was separated
by SDS-polyacrylamide gel electrophoresis (8%) (SDS-PAGE) and
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transferred onto polyvinylidene ﬂuoride (PVDF) membranes
(Immobilon®-FL, Millipore, Amsterdam-Zuidoost, Netherlands).
Membranes were probed with primary antibody, polyclonal rabbit anti-
CD63 (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and
monoclonal mouse anti-CD81 (1:100; Santa Cruz Biotechnology),
monoclonal anti-Grp94 (1:500, Santa Cruz Biotechnology) as negative
exosome marker. After incubation at 4 °C overnight, membranes were
washed in Tris buﬀered saline (pH 7.4) and incubated for 1 h at room
temperature with secondary antibody IRDye® 800CW or 680CW
Secondary Antibodies (LI-COR, Lincoln, Nebraska USA). Membranes
were analyzed using LI-COR Odissey Scanner (LI-COR, Lincoln,
Nebraska USA).
2.6. Treatment of HUVECs with exosomes for western blotting and qPCR
To study the eﬀect of exosomes from endothelial cells in BG or HG,
exosomes from HUVEC-HG or HUVEC-BG (exo-HG and exo-GB,
respectively) were incubated with either HUVEC-BG or HUVEC-HG
(Fig. 1). HUVECs in passage 2 were plated in 6 wells plates (Corning®
Costar®; Sigma-Aldrich, Zwijndrecht, The Netherlands). When 100%
conﬂuency was reached (∼3×105 cells per well) HUVECs were pre-
incubated for 24 h with medium containing 25mmol/L (high D-glucose)
or 5.5mmol/L (basal D-glucose). Cells were then washed and exposed to
exo-HG or exo-BG in exosome-free medium for further 12 h containing
two diﬀerent exosomal concentrations: 5 μg protein/mL (exo-BG 5 μg
exosomes from HUVEC-BG or exo-HG 5 μg exosomes from HUVEC-HG,
equivalent to∼2x105 vesicles per cm2) or 1 μg protein/mL (exo-BG 1 μg
for exosomes derived from BG or exo-HG 1 μg for exosomes derived
from HG, equivalent to ∼4x104 vesicles per cm2). The protein con-
centration of exosomes used in each experiment was based on previous
reports [21,28]. After the incubation period, cells were washed with
PBS and prepared for Western blotting or qPCR as [21,29] (see sup-
plemental material). Brieﬂy, the following primary antibodies were
used for Western blotting, monoclonal mouse anti-total eNOS (eNOS
Fig. 1. Representative scheme of exosome isolation and experimental design. A: exosomes were isolated from the supernatant of HUVECs exposed to basal
glucose (HUVEC-BG, 5mmol/L D-glucose) or high glucose (HUVEC-HG, 25mmol/L D-glucose) for 24 h incubation with exosome-free endothelial culture medium.
Exosomes from basal glucose and high glucose (exo-BG and exo-HG, respectively) were puriﬁed and characterized. B: HUVEC-BG and HUVEC-HG were exposed for
12 h with exosomes from both conditions, using 1 or 5 μg exosome protein/mL. HUVEC-BG or HUVEC-HG without exosome treatments were used as controls.
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1:2000; BD Transduction Laboratories™, CA, USA), monoclonal mouse
anti-phosphorylated eNOS at serine 1177 (P∼ Ser1177-eNOS 1:1000;
BD Transduction Laboratories™, CA, USA), polyclonal rabbit anti-
human cationic transporter type 1 (hCAT-1 1:200; abcam®, Cambridge,
UK), polyclonal rabbit anti-vascular endothelial growth factor (VEGF
1:200; abcam®, Cambridge, UK), monoclonal mouse anti-β-actin
(1:2500; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). In-
tensity of protein bands were quantiﬁed by densitometry using IMAGE
J software (https://imagej.nih.gov/ij/). For qPCR experiments the fol-
lowing primers were used: hCAT-1 (hCAT-1 (F): 5′-GAGTTAGATCCA
GCAGACCA-3’; hCAT-1 (R): 5′-TGTTCACAATTAGCCCAGAG-3′), eNOS
(eNOS (F): 5′-CCAGCTAGCCAAAGTCACCAT-3′; eNOS (R): 5′-GTCTCG
GAGCCATACAGGATT-3′) and VEGF (VEGF-A (F): 5′-TGCGGATCAAA
CCTCACCAA-3′; VEGF-A (R): 5′-TGTCACATACGC TCCAGGACTT-3′)
[30]; 28S (28S (F): 5′-TTGAAAATCCGGGGGAGAG-3′; and 28S anti-
sense (R): 5′-ACATTGTTCCAACATGCCAG-3′) was used as a reference
gene. For both experiments, HUVEC-BG and HUVEC-HG without exo-
somes were used as controls.
2.7. Wound healing assay
HUVECs were plated in 6 wells plates (Corning® Costar®; Sigma-
Aldrich, Zwijndrecht, The Netherlands) and the assay was performed as
described [21]. When 100% conﬂuence was reached, about
3× 105 cells per well, HUVECs were exposed for 24 h to high D-glucose
(25mmol/L) or basal D-glucose (5.5 mmol/L). Cells were washed with
PBS and incubated with exo-HG or exo-BG using 5 or 1 μg of exosome
protein as above. After 12 h incubation with exosomes a scratch was
made on a uniform conﬂuent layer of HUVECs using a sterile micro-
pipette tip and cells were washed with PBS to remove debris. Photo-
graphs (Leica MC 120 HD camera, ©Leica Microsystems, Amsterdam,
The Netherlands) of the same area of the wound were taken
Fig. 2. Exosomes from HUVECs exposed to basal or high-glucose. A: exosomes were isolated by the ultracentrifugation protocol from HUVECs cultured for 24 h in
basal glucose (HUVEC-BG, 5mmol/L D-glucose) or high glucose (HUVEC-HG, 25mmol/L D-glucose). After sucrose gradient, western blotting for CD63 and CD81 in
each fraction was performed. CD63 and CD81 were detected only in fraction 11 (arrows). B: Photographs from electronic microscopy showing exosomes in fraction
11 from cells as in A. C and D: Representative graphs for exosomes from fractions 11 using Nanosight (median=120 nm for exosomes from high glucose (exo-HG),
median=135 nm for exosomes from basal-glucose (exo-BG)). E: Concentration of exosomes from HUVEC-BG or HUVEC-HG. Data is shown as median with inter-
quartile range for NTA analysis for all experiments (n= 7). F: particle size as measured with NTA for all experiments (n= 7). P < 0.05 signiﬁcant (*), Wilcoxon
signed paired test.
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immediately after the scratch (0 h), after 4 h and 8 h, to measure the
area of the wound. The area under the curve, equivalent to wound
healing from time 0 to time 8, was measured using ImageJ (https://
imagej.nih.gov/ij/index.html). and expressed in arbitrary units for
wounded area at 4 and 8 h compared with time 0 h.
2.8. Flow cytometry analysis
To measure activation of HUVECs, ICAM-1 expression was mea-
sured using ﬂow cytometry. HUVECs were exposed for 24 h to culture
medium with HG or BG, followed by treatment with exo-HG or exo-
BGHG as described above (Fig. 1). After exosomal exposure, HUVECs
were prepared for ﬂow cytometry as described (see supplementary
material).
2.9. Statistical analysis
The normality of data distributions was evaluated using the Shapiro-
Wilk test. For comparison between HG and BG for exosome con-
centration and size the Wilcoxon signed test was used. For all other
data, two-way ANOVA test was used for testing the eﬀect of glucose
concentration and exosome incubation. For post-hoc test, a multiple
comparison test was conducted on the main eﬀects using the Sidak
adjustment. Data were analyzed using GraphPad Prism software (ver-
sion 7, San Diego). Values are expressed as median ± interquartile
range (exosomal concentration and size) or mean ± SD (other data).
P < 0.05 was considered to be signiﬁcant.
3. Results
3.1. High glucose enhanced the release but did not change the size of the
exosomes
Exosomes were characterized by anti-CD81 and anti-CD63 positive
staining detected only in fraction 11 (Fig. 2A). This fraction was used
for the subsequent experiments. Fraction 11 was studied by electron
microscopy and exosomes were found in all fractions 11 analyzed
(Fig. 2B). Exosomes were negative for Grp94 protein (Supplementary
Fig. 2). NTA showed that exosomes from HUVEC-BG had a median size
of∼135 nm (Fig. 2C), which is the expected size for exosomes [31]. HG
signiﬁcantly increased the concentration of exosomes in the super-
natant (Fig. 2E). The median size of the exo-HG was similar to the
median size of exo-BG (Fig. 2F).
3.2. High D-glucose and HUVEC-HG–exosomes increased endothelial cell
wound healing
HUVEC-HG showed increased endothelial cell wound-healing com-
pared with HUVEC-BG (Fig. 3A, left panels), as also evidenced by a
lower area under the curve (Fig. 3B). To evaluate whether this eﬀect of
HG was due to the presence of exosomes, HUVEC-BG were exposed to
exo-HG and HUVEC-HG to exo-BG in two concentrations (1 and 5 μg
protein/mL; the eﬀects for both concentrations were mainly similar,
although the eﬀects of 1 μg protein/mL were often less pronounced, so
data for 1 μg protein/mL exosomes are shown in the supplemental
ﬁles). Exo-HG increased endothelial cell wound healing in HUVEC-BG
as compared with HUVEC-BG without exosomes. Exo-BG did not alter
the wound healing in HUVEC-BG. In HUVEC-HG incubation with exo-
BG inhibited wound healing while exo-HG had no eﬀect on the wound
healing in HUVEC-HG.
3.3. High D-glucose and HUVEC-HG–exosomes activate eNOS
HG increased the protein level of P∼ Ser1177-eNOS, hCAT-1, and
VEGF but did not change total eNOS protein level (Fig. 4). Exo-HG
signiﬁcantly increased the protein levels of P∼ Ser1177-eNOS in
HUVEC-BG (Fig. 4C). Although the P∼ Ser1177eNOS protein level was
lower in HUVEC-HG in the presence of exo-BG, this result was not
statistically signiﬁcant. Total eNOS, hCAT-1, and VEGF protein levels
were unaltered by exosomes.
3.4. High D-glucose and HUVEC-exosomes modulate eNOS, hCAT-1 and
VEGF mRNA expression
The mRNA levels of eNOS and hCAT-1 were higher in HUVEC-HG as
compared with HUVEC-BG (Fig. 5). The eNOS and hCAT-1 mRNA re-
lative abundance was unaltered by exo-BG or exo-HG in HUVEC-BG.
However, exo-HG increased VEGF mRNA relative expression in HUVEC-
BG (Fig. 5C). Exo-BG reversed the HG-increased hCAT-1 but not eNOS
or VEGF mRNA relative expression. Exo-HG did not alter the HG-in-
creased eNOS or hCAT-1 but increased VEGF mRNA expression.
3.5. High D-glucose and HUVECs-exosomes modulate ICAM-1 expression
HG increased the expression of ICAM-1 in HUVECs (Fig. 6A and B).
Exo-HG and exo-BG increased ICAM-1 expression in HUVEC-BG as
compared to HUVEC-BG (Fig. 6A and B); however, HG-increased ICAM-
1 expression was unaltered by exo-BG or exo-HG.
4. Discussion
Our data conﬁrm our hypothesis that HG can induce endothelial cell
dysfunction in HUVECs by aﬀecting exosomes. Our results show en-
hanced endothelial cell wound healing, a stronger activation of the L-
arginine/NO signaling pathway and increased endothelial cell activa-
tion after incubation with HG. This eﬀect could be partly mimicked by
exposing HUVEC-BG to exosomes from HUVEC-HG. The resulting en-
dothelial phenotype has similarities with the phenotype of HUVECs
from GDM [21,23].
Incubation of HUVECs with HG increased the release of exosomes
without aﬀecting the size of these exosomes. This ﬁnding does not agree
with the ﬁndings reported by de Jong and colleagues [20] who was not
able to demonstrate an eﬀect of hyperglycemia on exosomal release
from human microvascular endothelial cells [20]. This might be ex-
plained by diﬀerences in the experimental setup such as using an adult
endothelial microvascular cell type instead of an immature neonatal
macrovascular endothelium and by the use of a lower D-glucose con-
centration (18mmol/L) compared with our study (25mmol/L). How-
ever, our results are in line with the ﬁndings reported by Rice and
colleagues showing that hyperglycemia increased the release of exo-
somes from trophoblasts [25]. Interestingly, also higher concentration
of exosomes are found in maternal blood from women diagnosed with
GDM [32], also suggesting that high glucose may induce the release of
exosomes.
HUVEC-HG showed increased endothelial cell wound healing
compared with HUVEC-BG. This is in line with other studies in which
exposure to HG induced an expedited retinal endothelial cell wound
healing capacity [33,34]. The increased wound healing capacity in HG
may result from increased endothelial cell proliferation or endothelial
cell migration. However, we did not discriminate between these pos-
sibilities in the present study. A possible mechanism for the increased
would healing capacity is the enhanced level of VEGF released by
HUVECs when exposed to HG [35]. In our study, although VEGF pro-
tein levels were increased in HUVEC-HG, this was not statistically sig-
niﬁcant. Interestingly, HUVECs isolated from GDM pregnancies grew
slower than HUVECs from healthy pregnancy, despite increased levels
of VEGF [8].
Our results show that exo-HG increased endothelial cell wound
healing, suggesting that the eﬀect of HG on endothelial cell wound
healing may be mediated by exosomes. The exo-HG eﬀect on wound
healing is associated with upregulation of VEGF production in HUVECs.
Our results are similar to those from Li and colleagues where exosomes
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Fig. 3. Eﬀect of high glucose and exosomes on endothelial cell wound healing. HUVECs cultured for 24 h in medium containing basal glucose (HUVEC-BG,
5 mmol/L D-glucose) or high glucose (HUVEC-HG, 25mmol/L D-glucose) were exposed to exosomes (5 μg protein/mL, 12 h) isolated from HUVEC-BG (exo-BG) or
HUVEC-HG (exo-HG). A: Wound healing assay in HUVECs. Area indicated with dotted lines was the wound area at time of scratch (t= 0) and after 8 h (t= 8) of
incubation with exoBG or exo-HG. B: the mean ± SD of the area under curve (AUC) of the wound healing from 0 to 8 h (n= 8). Two-way ANOVA and Sidak post-hoc
analysis was performed. P < 0.05 signiﬁcant (*) vs HUVEC-BG control and between corresponding groups.
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from endothelial progenitor cells increased migration of a human mi-
crovascular endothelial cell line in a wound healing assay [36]. Similar
to our results, in the latter study upregulation of proangiogenic mole-
cules such as VEGF was induced by exosomes [36]. Exo-BG incubated
with HUVEC-HG seemed to be able to restore HUVEC-HG wound
healing capacity to that seen in HUVEC-BG.
A potential limitation of our study refers to the fact that HUVECs
were exposed for 24 h to HG and then further incubated with exo-BG for
12 h in the presence of basal glucose levels. Thus, the possibility exists
that reversal of the wound healing capacity may be due to restoration of
HUVECs functionality due to withdrawal of HG. However, HUVEC-HG
cultured in BG in the absence of exo-BG did not show restoration of the
wound healing capacity following removal of high extracellular con-
centrations of D-glucose. Moreover, there is increasing evidence
showing that normalizing maternal glycaemia in gestational diabetes
mellitus results in normoglycaemia in the growing fetus and the oﬀ-
spring at delivery [10,29,37]. However, even when reaching a normal
glycaemia in the mother, fetus and oﬀspring following diet, insulin
therapy or a change in life-style, alterations in the fetoplacental en-
dothelial function are still seen. Together these data show that removal
Fig. 4. Eﬀect of high glucose and exosomes on eNOS, hCAT-1, and VEGF protein expression. HUVECs cultured for 24 h in medium containing basal glucose
(HUVEC-BG, 5 mmol/L D-glucose) or high glucose (HUVEC-HG, 25mmol/L D-glucose) were exposed to exosomes (1 or 5 μg protein/mL, 12 h) isolated from HUVEC-
BG (exo-BG) or HUVEC-HG (exo-HG). A: Representative Western blots for phosphorylated endothelial nitric oxide synthase (eNOS) at serine1177 (P∼ Ser1177-eNOS),
total eNOS, human cationic amino acid transporter 1 (hCAT-1), and vascular endothelial cell growth factor (VEGF). β-Actin was a loading control. B–E: Analysis of
Western blots for phosphorylated eNOS (P∼ Ser1177-eNOS)/total eNOS (B), total eNOS/β-actin (D), hCAT-1/β-actin (C) and VEGF/β-actoin (E) ratios (n=8).
Analysis of the results using exosomes at 1 μg protein/mL are shown in Supplementary Fig. 3). Data are express as mean ± SD and two-way ANOVA and Sidak post-
hoc analysis was performed. P < 0.05 signiﬁcant (*) vs HUVEC-BG control and between corresponding groups.
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of D-glucose from the medium may not be a plausible explanation, but
that HUVEC-derived exosomes may induce this restoration.
The present study shows that HG increased the activator Ser1177-
phosphorylation of eNOS, hCAT-1 and VEGF protein expression in
HUVECs. Similar results data have been shown by Vasquez and col-
leagues [16], where exposure of HUVECs to 25mmol/L for 24 h in-
creased the phosphorylation of Ser1177 at eNOS and NO synthesis, and
hCAT-1 expression in addition to increased L-arginine transport. We
show that some of the eﬀects of HG on HUVECs can also be induced by
exo-HG in HUVECs incubated under BG conditions. We found that exo-
HG increased the level of P∼Ser1177-eNOS, and hCAT1 and VEGF
protein expression, although this was only signiﬁcant for P∼Ser1177-
eNOS expression. Although similar data were found for mRNA ex-
pression, the protein data are not always consistent with mRNA data in
our study. This may be due for instance to the well-known fact that
there are many post-transcriptional modiﬁcations during translation of
mRNA into protein [38]. These results show that exo-HG can partly
induce a HG phenotype in HUVEC-BG and are therefore in line with the
hypothesis that HG induces the production of exosomes in fetal en-
dothelium and that these exosomes negatively impact fetal endothelial
function. Interestingly, exo-BG restored the P∼Ser1177-eNOS level in
HUVEC-HG to values in HUVEC-BG. Exo-BG also seemed to be able to
restore the endothelial expression of hCAT-1 and VEGF, although this
was not statistical signiﬁcant. As indicated above, these results for exo-
BG incubation may also be due to restoration of endothelial function
following removal of HG. Future studies are needed to evaluate whether
diﬀerences in exosomal cargo between exo-HG and exo-BG are re-
sponsible for the diﬀerences in response of HUVECs to these exosomes.
Proteomic analysis seems to be necessary to explain this diﬀerence.
HUVECs incubated under HG showed increased endothelial cell
Fig. 5. Eﬀect of high glucose and exosomes on eNOS, hCAT-1 and VEGF mRNA expression. HUVECs cultured for 24 h in medium containing basal glucose
(HUVEC-BG, 5 mmol/L D-glucose) or high glucose (HUVEC-HG, 25mmol/L D-glucose) were exposed to exosomes (5 μg protein/mL, 12 h) isolated from HUVEC-BG
(exo-BG) or HUVEC-HG (exo-HG). Fold change of relative mRNA expression for (A) endothelial nitric oxide synthase (eNOS), (B) human cationic amino acid
transporter 1 (hCAT-1), and (C) vascular endothelial cell growth factor (VEGF) are shown. Values were normalized to a 28S mRNA. Data are express as mean ± SD
and two-way ANOVA and Sidak post-hoc analysis was performed. P < 0.05 signiﬁcant (*) vs HUVEC-BG control and between corresponding groups.
Fig. 6. Eﬀect of high glucose and exosomes on ICAM-1 expression. HUVECs cultured for 24 h in medium containing basal glucose (HUVEC-BG, 5mmol/L D-
glucose) or high glucose (HUVEC-HG, 25mmol/L D-glucose) were exposed to exosomes (5 μg protein/mL, 12 h) isolated from HUVEC-BG (exo-BG) or HUVEC-HG
(exo-HG). A: Representative dot plots for intracellular adhesion molecule type 1 (ICAM-1) in HUVECs in the absence (Control) or presence of exosomes. B: Data are
presented as percentage of ICAM-1 positive cells for the various conditions (n= 5). Data are express as mean ± SD and two-way ANOVA and Sidak post-hoc analysis
was performed. P < 0.05 signiﬁcant (*) vs HUVEC-BG control.
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activation, as quantiﬁed by the expression of ICAM-1. Previous studies
have also shown that HG can activate endothelial cells by increasing
expression of this adhesion molecule [39,40]. Since HUVECs from GDM
pregnancies also express high levels of ICAM-1 [41], HG may be one of
the responsible factors for fetoplacental endothelial cell activation in
GDM. Moreover, the expression of ICAM-1 is lower in HUVECs from
women with GDM with HbA1c levels lower than 6% as compared with
women with normal pregnancies, suggesting these diﬀerences can be
due to diﬀerences in D-glucose management [42]. Although we found
that this upregulation of ICAM-1 could also be induced by exo-HG,
which is in line with our hypothesis, in contrast to our hypothesis,
endothelial cell activation was also induced by exo-BG. The reason for
this is unknown, but since ICAM-1 has been described as constitutive
protein of exosomal cargo in other cell types, such as immune cells
[27], it is possible that endothelial exosomes may also contain ICAM-1,
which could be transferred to endothelial cells even under basal D-
glucose condition.
Interestingly, exosomes derived from HUVEC-HG induced changes
in wound healing capacity and eNOS activity in HUVEC-BG supporting
previous results from our lab seen in HUVECs from GDM [21]. Exo-
somes derived from HUVECs from GDM increased the wound healing
capacity and eNOS activity in HUVECs from normal pregnancies.
Therefore, a paracrine action of exosomes in fetal endothelial cells in
GDM pregnancies is likely, a phenomenon that may result in spreading
the GDM-associated pathological phenotype to the fetoplacental en-
dothelium inducing endothelial dysfunction of this vascular bed [23].
In summary, HG induced endothelial cell dysfunction and activation
in HUVECs that is partly similar to the endothelial cell dysfunction and
activation seen in this cell type from GDM pregnancies [21]. The results
showed that HUVECs-derived exosomes have the capacity to modulate
HUVECs function, such as their wound healing capacity and eNOS ac-
tivation, under normal or high extracellular D-glucose concentration.
Future studies are needed to evaluate whether exosomes are inter-
nalized by HUVECs and whether high extracellular D-glucose aﬀects the
internalization of these nanovesicles. Although incubation of HUVECs
with HG mimicked several features of a state of endothelial cell dys-
function as seen in HUVECs from GDM pregnancies, exposure of HU-
VECs to HG cannot totally explain the phenotype of this cell type in
GDM. Thus, it is suggested that other factors, such as fetal hyper-
insulinemia and elevated levels of proinﬂammatory factors, may also
play a role. Our ﬁndings suggest that fetoplacental endothelial exo-
somes are one of the mechanisms behind endothelial dysfunction in-
duced by an intrauterine environment high in D-glucose concentration
as seen at some stages in GDM.
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